Evidence map›Paper›PMID 42706590›Full record

ArticleGeneral thoracic and cardiovascular surgery cases2026

Lessons from surgery after neoadjuvant chemoimmunotherapy for bulky, invasive N2 lung cancer: a case report.

Teppei Hashimoto, Kanji Tanaka, Yasuhiro Fujita, Takehiko Manabe, Hiroki Matsumiya, Masataka Mori, Masaru Takenaka, Koji Kuroda, Fumihiro Tanaka, Hidetaka Uramoto

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in General thoracic and cardiovascular surgery cases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Teppei HashimotoSecond Department of Surgery, Japan School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi- ku, Kitakyushu, Fukuoka, 807-8556, Japan. teppei3330@med.uoeh-u.ac.jp.ORCID http://orcid.org/0000-0002-6973-7284
Kanji TanakaSecond Department of Surgery, Japan School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi- ku, Kitakyushu, Fukuoka, 807-8556, Japan.
Yasuhiro FujitaSecond Department of Surgery, Japan School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi- ku, Kitakyushu, Fukuoka, 807-8556, Japan.
Takehiko ManabeSecond Department of Surgery, Japan School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi- ku, Kitakyushu, Fukuoka, 807-8556, Japan.
Hiroki MatsumiyaSecond Department of Surgery, Japan School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi- ku, Kitakyushu, Fukuoka, 807-8556, Japan.
Masataka MoriSecond Department of Surgery, Japan School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi- ku, Kitakyushu, Fukuoka, 807-8556, Japan.
Masaru TakenakaSecond Department of Surgery, Japan School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi- ku, Kitakyushu, Fukuoka, 807-8556, Japan.
Koji KurodaSecond Department of Surgery, Japan School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi- ku, Kitakyushu, Fukuoka, 807-8556, Japan.
Fumihiro TanakaSecond Department of Surgery, Japan School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi- ku, Kitakyushu, Fukuoka, 807-8556, Japan.
Hidetaka UramotoSecond Department of Surgery, Japan School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi- ku, Kitakyushu, Fukuoka, 807-8556, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeoadjuvant nivolumab plus chemotherapy increases pathologic complete response rates in resectable non-small cell lung cancer, but the operative safety of this approach in bulky, invasive N2 disease with suspected great-vessel involvement remains uncertain. CASE PRESENTATION: A 64-year-old woman had left upper lobe adenocarcinoma with bulky single-station N2a disease and suspected aortic arch invasion. After three cycles of nivolumab plus carboplatin-paclitaxel, imaging showed only limited nodal shrinkage. At lobectomy, the subaortic lymph node was broadly adherent to the arch and surrounding structures, causing hemorrhage that required cardiopulmonary bypass and arch resection. Pathology showed pathologic complete response, but lymphocyte-predominant inflammation and fibrosis extended to the aortic adventitia.

conclusionsRadiographic response and pathologic complete response after chemoimmunotherapy do not necessarily indicate safe technical resectability in bulky, invasive N2 lung cancer. Multidisciplinary surgical planning should preserve caution when great-vessel invasion is suspected.

Indexed as

Aortic arch resectionBulky N2 diseaseCardiopulmonary bypassCase reportNeoadjuvant chemoimmunotherapyNon-small cell lung cancerPathologic complete response

Identifiers

PMID42706590
PMCPMC13551823

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.